These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20680533)

  • 21. Long-term anticoagulation prophylaxis following acute thromboembolism.
    Hyers TM
    Dis Mon; 2005; 51(2-3):158-65. PubMed ID: 15900268
    [No Abstract]   [Full Text] [Related]  

  • 22. A 10 mg warfarin initiation nomogram is safe and effective in outpatients starting oral anticoagulant therapy for venous thromboembolism.
    Monkman K; Lazo-Langner A; Kovacs MJ
    Thromb Res; 2009 Jul; 124(3):275-80. PubMed ID: 19155056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of warfarin therapy among residents who developed venous thromboembolism in the nursing home.
    Reardon G; Pandya N; Nutescu EA; Lamori J; Damaraju CV; Schein J; Bookhart BK
    Am J Geriatr Pharmacother; 2012 Dec; 10(6):361-72. PubMed ID: 23217529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Duration of anticoagulant therapy for patients with venous thromboembolism.
    Garcia D
    Thromb Res; 2008; 123 Suppl 1():S62-4. PubMed ID: 18823648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venous thromboembolism in pregnancy.
    James AH
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):326-31. PubMed ID: 19228606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
    Agnelli G; Prandoni P; Santamaria MG; Bagatella P; Iorio A; Bazzan M; Moia M; Guazzaloca G; Bertoldi A; Tomasi C; Scannapieco G; Ageno W;
    N Engl J Med; 2001 Jul; 345(3):165-9. PubMed ID: 11463010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term anticoagulation for venous thromboembolism: duration of treatment and management of warfarin therapy.
    Kearon C
    Clin Chest Med; 2010 Dec; 31(4):719-30. PubMed ID: 21047578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting.
    Willey VJ; Bullano MF; Hauch O; Reynolds M; Wygant G; Hoffman L; Mayzell G; Spyropoulos AC
    Clin Ther; 2004 Jul; 26(7):1149-59. PubMed ID: 15336480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
    Reeves D; Liu CY
    J Oncol Pharm Pract; 2010 Mar; 16(1):27-31. PubMed ID: 19401307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery.
    Enyart JJ; Jones RJ
    Ann Pharmacother; 2005 Jun; 39(6):1002-7. PubMed ID: 15886295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sublingual administration of warfarin: a novel form of delivery.
    Batke-Hastings S; Carman TL
    Vasc Med; 2008; 13(2):123-6. PubMed ID: 18593801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Practical application of the 10-mg warfarin initiation nomogram.
    Wells PS; Le Gal G; Tierney S; Carrier M
    Blood Coagul Fibrinolysis; 2009 Sep; 20(6):403-8. PubMed ID: 19521238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism.
    Tran HA
    N Engl J Med; 2003 Nov; 349(22):2164-7; author reply 2164-7. PubMed ID: 14658126
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    Francis CW; Berkowitz SD; Comp PC; Lieberman JR; Ginsberg JS; Paiement G; Peters GR; Roth AW; McElhattan J; Colwell CW;
    N Engl J Med; 2003 Oct; 349(18):1703-12. PubMed ID: 14585938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous heparin for prophylaxis of venous thromboembolism in deep brain stimulation surgery: evidence from a decision analysis.
    Bauman JA; Church E; Halpern CH; Danish SF; Zaghloul KA; Jaggi JL; Stein SC; Baltuch GH
    Neurosurgery; 2009 Aug; 65(2):276-80; discussion 280. PubMed ID: 19625905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment patterns and outcomes among hospitalized patients with venous thromboembolism in the United States: an analysis of electronic health records data.
    Menzin J; Preblick R; Friedman M; Menzin J; Frean M; Jacqueline Kwong W
    Hosp Pract (1995); 2014 Oct; 42(4):59-74. PubMed ID: 25502130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism.
    Veeger NJ; Piersma-Wichers M; Tijssen JG; Hillege HL; van der Meer J
    Br J Haematol; 2005 Feb; 128(4):513-9. PubMed ID: 15686461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low rate of warfarin-related major bleeding in patients with recurrent venous thromboembolism.
    Prandoni P; Lensing AW; Bagatella P; Simioni P; Girolami A
    Thromb Haemost; 1999 Jul; 82(1):158-9. PubMed ID: 10456478
    [No Abstract]   [Full Text] [Related]  

  • 39. Bleeding complications and mortality in warfarin-treated VTE patients, dependence of INR variability and iTTR.
    Sandén P; Renlund H; Svensson PJ; Själander A
    Thromb Haemost; 2017 Jan; 117(1):27-32. PubMed ID: 27652593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism.
    Ridker PM; Goldhaber SZ; Glynn RJ
    N Engl J Med; 2003 Nov; 349(22):2164-7; author reply 2164-7. PubMed ID: 14658125
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.